Fri, November 11, 2011
Thu, November 10, 2011
Wed, November 9, 2011
Tue, November 8, 2011
Mon, November 7, 2011
[ Mon, Nov 07th 2011 ]: Market Wire
30 a.m. ET
Sun, November 6, 2011
Sat, November 5, 2011
Fri, November 4, 2011
Thu, November 3, 2011
Wed, November 2, 2011
Tue, November 1, 2011
Mon, October 31, 2011
Sat, October 29, 2011
Fri, October 28, 2011
Thu, October 27, 2011

Regeneron Announces Presentation at the 2011 Credit Suisse Annual Healthcare Conference


//health-fitness.news-articles.net/content/2011/ .. -credit-suisse-annual-healthcare-conference.html
Published in Health and Fitness on by Market Wire   Print publication without navigation


Regeneron Announces Presentation at the 2011 Credit Suisse Annual Healthcare Conference -- TARRYTOWN, N.Y., Nov. 7, 2011 /PRNewswire/ --

Regeneron Announces Presentation at the 2011 Credit Suisse Annual Healthcare Conference

[ ]

TARRYTOWN, N.Y., Nov. 7, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: [ REGN ]) will webcast its presentation at the 2011 Credit Suisse Annual Healthcare Conference on Wednesday, November 9, 2011.  The presentation is scheduled for 9:30 a.m. Mountain Time (11:30 a.m. Eastern Time).  The session may be accessed through the Company's web site, [ www.regeneron.com ], on the Investor Relations page.  An archived version of the presentation will be available after the live webcast through December 9, 2011.  

Regeneron is a fully integrated biopharmaceutical company that discovers, develops, manufacturers, and commercializes medicines for the treatment of serious medical conditions. In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, which is approved for the treatment of a rare inflammatory condition, Regeneron has completed Phase 3 clinical trials of rilonacept for a new indication and of product candidates EYLEA™ (aflibercept injection; VEGF Trap-Eye) in diseases of the eye and ZALTRAP® (aflibercept; VEGF Trap) in colorectal cancer.  EYLEA is currently under review with U.S. and European regulatory authorities.  Additional therapeutic candidates developed from proprietary Regeneron technologies for creating fully human monoclonal antibodies are in earlier stage development programs in rheumatoid arthritis, pain, cholesterol reduction, allergic and immune conditions, and cancer.  Additional information about Regeneron and recent news releases are available on Regeneron's web site at [ www.regeneron.com ].

Contact Information:




Michael Aberman, M.D.

Peter Dworkin

Investor Relations

Corporate Communications

914.847.7799

914.847.7640

[ michael.aberman@regeneron.com ]

[ peter.dworkin@regeneron.com ]



SOURCE Regeneron Pharmaceuticals, Inc.

[ Back to top ]

RELATED LINKS
[ http://www.regeneron.com ]


Publication Contributing Sources

Publication Sponsors
[ Last Sunday ] - Oceanside Rental Gear